Intracerebral hemorrhage after intravenous t-PA therapy for ischemic stroke

Stroke

Volumn 28, Issue 11, 1997, Pages 2109-2118

  Broderick, Joseph P ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

Cerebral ischemia; Clinical trials; Computed tomography; Intracerebral hemorrhage; Thrombolytic therapy

Indexed keywords

TISSUE PLASMINOGEN ACTIVATOR;

ARTICLE; BRAIN BLOOD FLOW; BRAIN EDEMA; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FIBRINOLYTIC THERAPY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STROKE; TREATMENT INDICATION;

EID: 0343118114     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.str.28.11.2109     Document Type: Article

References (25)

1. National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995;333:1581-1587.
2. Von Kummer R, Bozzao L, Bastianello S, Manelfe C, for the ECASS Group. Extent of ischemic brain edema and the response to plasminogen activator in acute hemispheric stroke. Stroke. 1997; 28:270. Abstract.
3. Brott TG, Adams HP Jr, Olinger CP, Marler JR, Barsan WG, Biller J, Spilker J, Holleran R, Eberle R, Hertzberg V, Rorick M, Moomaw CJ, Walker M. Measurements of acute cerebral infarction: a clinical examination scale. Stroke. 1989;20:864-870.
4. Van Swieten JC, Koudstaal PJ, Visser MC, Schouten HJA, van Gijn J. Interobserver agreement for the assessment of handicap in stroke patients. Stroke. 1988;19:604-607.
5. Mahoney FI, Barthel DW. Functional evaluation: the Barthel Index. Md State Med J. 1965;14(2):61-65.
6. Jennett B, Bond M. Assessment of outcome after severe brain injury: a practical scale. Lancet. 1975;1:480-484.
7. Hosmer DW and Lemeshow S. Applied Logistic Regression. New York, NY: John Wiley & Sons; 1989.
8. Copas JB. Regression prediction and shrinkage (with discussion). J R Stat Soc (Series B). 1983;45:311-354.
9. Galen RS, Gambino SR. Beyond Normality: The Predictive Value and Efficiency of Medical Diagnoses. New York, NY: John Wiley & Sons; 1975.
10. The NINDS rt-PA Stroke Study Group. Generalized efficacy of t-PA for acute stroke: subgroup analysis of the NINDS t-PA Stroke Trial. Stroke. 1997;28:2119-2125.
11. Hacke W, Kaste M, Fieschi C, Toni D, Lesaffre E, von Kummer R, Boysen G, Bluhmki E, Hoxter G, Mahagne MH. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. JAMA. 1995;274:1017-1025.
12. Larrue V, von Kummer R, del Zoppo G, Bluhmki E. Hemorrhagic transformation in acute ischemic stroke: potential contributing factors in the European Cooperative Acute Stroke Study. Stroke. 1997;28:957-960.
13. Fleming TR. Interpretation of subgroup analyses in clinical trials. Drug Information J. 1995;29:1681S-1687S.
14. Levy DE, Brott TG, Haley EC Jr, Marler JR, Sheppard GL, Barsan W, Broderick JP. Factors related to intracranial hematoma formation inpatients receiving tissue-type plasminogen activator for acute ischemic stroke. Stroke. 1994;25:291-297.
15. Gore JM, Granger CB, and Simoons ML, Sloan MA, Weaver WD, White HD, Barbash GI, van de Werf F, Aylward PE, Topol EJ. Stroke after thrombolysis: mortality and functional outcomes in the GUSTO-I Trial. Circulation. 1995;92:2811-2818.
16. Selker HP, Beshansky, JR, Schmid CH, Griffith JL, Longstreth WT Jr, O'Connor CM, Caplan LP, Massey EW, D'Agostino RB, Laks MM. Presenting pulse pressure predicts thrombolytic therapy-related intracranial hemorrhage: thrombolytic predictive instrument (TPI) project results. Circulation. 1994;90:1657-1661.
17. Simoons ML, Maggioni AP, Knatterud G, Leimberger JC, de Jaegere P, Van Domburg R, Boersma E, Franzosi MG, Califf R, Schroder R. Individual risk assessment for intracranial haemorrhage during thrombolytic therapy. Lancet. 1993;342:1523-1528.
18. Zlokovic BV, Wang L, Kittaka M, Berislav V, Schreiber S, Mark J Fisher E, Ning S. Nicotine enhances focal ischemic stroke in rats. Stroke. 1996;27:166. Abstract.
19. del Zoppo GJ, Poeck K, Pessin MS, Wolpert SM, Furlan AJ, Ferbert A, Alberts MJ, Zivin JA, Wechsler L, Busse O, Greenlee R Jr, Brass L, Mohr JP, Feldman E, Hacke W, Kase CS, Biller J, Gress D, Otis SM. Recombinant tissue plasminogen activator in acute thrombotic and embolic stroke. Ann Neurol. 1992;32:78-85.
20. Wolpert SM, Bruckmann H, Greenlee R, Wechsler L, Pessin MS, del Zoppo GJ, and the rt-PA Acute Stroke Study Group. Neuroradiologic evaluation of patients with acute stroke treated with recombinant tissue plasminogen activator. AJNR Am J Neuroradiol. 1993;14:3-13.
21. Multicentre Acute Stroke Trial-Italy (MAST-1) Group. Randomized controlled trial of streptokinase, aspirin, and combination of both in treatment of acute ischemic stroke. Lancet. 1995;346: 1509-1514.
22. The Multicenter Acute Stroke Trial-European Study Group. Thrombolytic therapy with streptokinase in acute ischemic stroke. N Engl J Med. 1996;335:145-150.
23. Donnan GA, Davis SM, Chambers BR, Gates PC, Hankey GJ, McNeil JJ, Rosen D, Stewart-Wynne EG, Tuck RR. Letter to the editor. Lancet. 1995;345:578-579.
24. North American Symptomatic Carotid Endarterectomy Trial Collaborators. Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade stenosis. N Engl J Med. 1991;325: 445-453.
25. Riggs JE. Tissue-type plasminogen activator should not be used in acute ischemic stroke. Arch Neurol. 1996;53:1306-1307.